vs
Side-by-side financial comparison of Essent Group Ltd. (ESNT) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -0.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 2.3%).
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESNT vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $312.4M | $168.4M |
| Net Profit | $155.0M | — |
| Gross Margin | — | — |
| Operating Margin | 59.1% | 50.6% |
| Net Margin | 49.6% | — |
| Revenue YoY | -0.8% | 143.7% |
| Net Profit YoY | -7.7% | — |
| EPS (diluted) | $1.61 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $312.4M | $168.4M | ||
| Q3 25 | $311.8M | $87.3M | ||
| Q2 25 | $319.1M | $82.4M | ||
| Q1 25 | $317.6M | $65.0M | ||
| Q4 24 | $315.0M | $69.1M | ||
| Q3 24 | $316.6M | $51.6M | ||
| Q2 24 | $312.9M | $73.8M | ||
| Q1 24 | $298.4M | $137.7M |
| Q4 25 | $155.0M | — | ||
| Q3 25 | $164.2M | $-31.3M | ||
| Q2 25 | $195.3M | $-12.7M | ||
| Q1 25 | $175.4M | $-40.5M | ||
| Q4 24 | $167.9M | — | ||
| Q3 24 | $176.2M | $-29.5M | ||
| Q2 24 | $203.6M | $-61.9M | ||
| Q1 24 | $181.7M | $61.0M |
| Q4 25 | 59.1% | 50.6% | ||
| Q3 25 | 63.9% | -11.4% | ||
| Q2 25 | 72.4% | 8.6% | ||
| Q1 25 | 65.2% | -34.0% | ||
| Q4 24 | 61.9% | -6.4% | ||
| Q3 24 | 65.6% | -31.0% | ||
| Q2 24 | 76.4% | 3.5% | ||
| Q1 24 | 71.6% | 52.5% |
| Q4 25 | 49.6% | — | ||
| Q3 25 | 52.7% | -35.9% | ||
| Q2 25 | 61.2% | -15.4% | ||
| Q1 25 | 55.2% | -62.2% | ||
| Q4 24 | 53.3% | — | ||
| Q3 24 | 55.6% | -57.2% | ||
| Q2 24 | 65.1% | -83.9% | ||
| Q1 24 | 60.9% | 44.3% |
| Q4 25 | $1.61 | $0.32 | ||
| Q3 25 | $1.67 | $-0.16 | ||
| Q2 25 | $1.93 | $-0.06 | ||
| Q1 25 | $1.69 | $-0.21 | ||
| Q4 24 | $1.59 | $-0.14 | ||
| Q3 24 | $1.65 | $-0.15 | ||
| Q2 24 | $1.91 | $-0.33 | ||
| Q1 24 | $1.70 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.8B | $-302.0M |
| Total Assets | $7.4B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $5.8B | $-302.0M | ||
| Q3 25 | $5.7B | $-451.4M | ||
| Q2 25 | $5.7B | $-433.5M | ||
| Q1 25 | $5.7B | $-426.2M | ||
| Q4 24 | $5.6B | $-388.7M | ||
| Q3 24 | $5.6B | $-370.2M | ||
| Q2 24 | $5.4B | $-344.2M | ||
| Q1 24 | $5.2B | $-294.3M |
| Q4 25 | $7.4B | $465.9M | ||
| Q3 25 | $7.4B | $364.0M | ||
| Q2 25 | $7.2B | $347.1M | ||
| Q1 25 | $7.2B | $324.0M | ||
| Q4 24 | $7.1B | $343.8M | ||
| Q3 24 | $7.1B | $314.1M | ||
| Q2 24 | $6.7B | $352.3M | ||
| Q1 24 | $6.6B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $856.1M | $45.2M |
| Free Cash FlowOCF − Capex | $848.7M | — |
| FCF MarginFCF / Revenue | 271.7% | — |
| Capex IntensityCapex / Revenue | 2.4% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $856.1M | $45.2M | ||
| Q3 25 | $215.9M | $-4.3M | ||
| Q2 25 | $189.5M | $-31.4M | ||
| Q1 25 | $221.6M | $-22.6M | ||
| Q4 24 | $861.5M | $-35.0M | ||
| Q3 24 | $229.2M | $-35.3M | ||
| Q2 24 | $188.7M | $-7.2M | ||
| Q1 24 | $216.9M | $53.8M |
| Q4 25 | $848.7M | — | ||
| Q3 25 | $210.6M | — | ||
| Q2 25 | $188.8M | — | ||
| Q1 25 | $221.3M | — | ||
| Q4 24 | $854.8M | — | ||
| Q3 24 | $228.7M | $-35.5M | ||
| Q2 24 | $187.6M | $-7.3M | ||
| Q1 24 | $212.5M | $53.8M |
| Q4 25 | 271.7% | — | ||
| Q3 25 | 67.5% | — | ||
| Q2 25 | 59.2% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 271.3% | — | ||
| Q3 24 | 72.2% | -68.7% | ||
| Q2 24 | 60.0% | -9.9% | ||
| Q1 24 | 71.2% | 39.0% |
| Q4 25 | 2.4% | 0.0% | ||
| Q3 25 | 1.7% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q1 25 | 0.1% | 0.0% | ||
| Q4 24 | 2.1% | 0.0% | ||
| Q3 24 | 0.2% | 0.3% | ||
| Q2 24 | 0.3% | 0.1% | ||
| Q1 24 | 1.5% | 0.1% |
| Q4 25 | 5.52× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 5.13× | — | ||
| Q3 24 | 1.30× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 1.19× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
